KU-32, a Novel Drug for Diabetic Neuropathy, Is Safe for Human Islets and Improves In Vitro Insulin Secretion and Viability
Figure 3
KU-32 increased insulin secretion. (a) In perifusion experiments, exposure to KU-32 increased insulin secretion in response to high-glucose. Initially, islets were maintained in 3 mM glucose. At time 0, the perfusate was switched to 17.3 mM glucose (high-glucose conditions). After 30 minutes, the glucose level was returned to 3 mM. During the high-glucose stimulation, there was significantly more insulin released by the KU-32-treated islets compared to the vehicle-treated. During low-glucose exposure, there was no difference between the 2 groups. (*indicates , separate trials). (b) Insulin secretion measured during static incubation resulted in similar findings with statistically more insulin released in high glucose from the KU-32-treated islets. (*indicates ).
